Tracers / [177Lu]Lu-DOTA-Rituximab

[177Lu]Lu-DOTA-Rituximab

Also written as [Lu-177]Lu-DOTA-Rituximab; [Lu-177]Lu-DOTA-rituximab; Lu-177-DOTA-Rituximab; Lu-177-DOTA-rituximab
Radionuclide
Lu-177 t½ 9584.6 min
Modality
Therapy
Production route
—
Stage
—
Syntheses indexed
2
LymphomaDosimetry and biodistribution studies

What it is

Compound class
Anti-CD20 monoclonal antibody (rituximab) conjugated with DOTA chelator (radioimmunoconjugate)
Target / mechanism
CD20 antigen on B-cells (via rituximab antibody) PMID 27980563
Clinical application
Radioimmunotherapy of Non-Hodgkin's lymphoma PMID 27980563
Theranostic pair
—

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Kit-based preparation—none98.7% to 99.0%>98%DOTA-SCN (p-SCN-Bn-DOTA)
Macrocyclics
30568680
2018 Iran J Pharm Res
the freeze-dried kit containing 2.0 mg of DOTA-anti-CD20 was dissolved in 0.5 mL of water and mixed with 100-900 MBq of [177Lu]LuCl3 or 90YCl3 — the radiochemical yield ranging from 98.7% to 99.0% and from 98.8% to 99.1% at 1 h for 177Lu-DOTA-Rituximab and 90Y-DOTA-Rituximab respectively
—————p-SCN-Bn-DOTA
Macrocyclics
27980563
2016 Iran J Pharm Res

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-Rituximab, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 30568680: 'p-SCN-Bn-DOTA(2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)'.